Abiopharma

News list

Landry Robert E 🟢 acquired 19.2K shares (2 derivative) of Zymeworks Inc. (ZYME) at $23.16 Transaction Date: Jan 12, 2026 | Filing ID: 010859

Full text

News bot Jan. 13, 2026, 1:58 a.m.
🔍 Landry Robert E (Executive)

Company: Zymeworks Inc. (ZYME)

Report Date: 2026-01-12
Transaction Summary:
- Total transactions: 2
- Derivative instruments: 2
- Holdings reported: 0
- Total shares acquired: 19,200
Detailed Transactions and Holdings:
- Acquired 11,500 shares of Stock Option (Right to Buy) at $23.16 per share (Derivative)
  Date: 2026-01-12 | Code: A | Expires: 2036-01-11 | Exercise: 2027-01-12 | equity_swap_involved: false | shares_owned_after: 11,500.00 | transaction_form_type: 4 | Footnotes: F1
- Acquired 7,700 shares of Restricted Stock Unit (Derivative)
  Date: 2026-01-12 | Code: A | Expires: 2027-01-12 | Exercise: 2027-01-12 | equity_swap_involved: false | shares_owned_after: 7,700.00 | transaction_form_type: 4 | Footnotes: F2, F3, F3
Footnotes:
- F1: Stock options vest on January 12, 2027.
- F2: Each restricted stock unit ("RSU") represents the contingent right to receive, upon vesting of the RSU, one share of common stock.
- F3: RSUs vest on January 12, 2027.